Bumetanide Inj Rx
Generic Name and Formulations:
Bumetanide 0.25mg/mL; contains benzyl alcohol.
Various generic manufacturers
Indications for Bumetanide Inj:
Initially 0.5–1mg IM or IV. May give 1–2 more doses at 2–3 hour intervals; max 10mg/day.
<18yrs: not recommended.
Anuria. Infants. Hepatic coma. Severe electrolyte depletion.
Hepatic cirrhosis. Ascites. Progressive renal disease. Gout. Diabetes. Postsympathectomy. Monitor electrolytes, blood, liver function. May need K+ supplementation. K+ losing nephropathy. Discontinue if renal dysfunction progresses. Aldosterone excess. Ventricular arrhythmias. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
May increase digitalis, lithium toxicity. Hypokalemia with digitalis, diuretics in CHF. Alcohol, CNS depressants increase orthostatic hypotension. Avoid probenecid, indomethacin. Ototoxicity may be potentiated with aminoglycosides.
Muscle cramps, dizziness, hypotension, headache, nausea, encephalopathy, ototoxicity, rash, fluid or electrolyte imbalance, hyperglycemia, hyperuricemia, blood dyscrasias.
Formerly known under the brand name Bumex.
Neurology Advisor Articles
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Serious Adverse Events Profile for Cladribine Confirmed With Extended Data
- Patients With Multiple Sclerosis Face Greater Infection Risk
- Ozanimod Reduces Severe Relapses in Multiple Sclerosis More Than Interferon Beta-1a